Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.22+0.09 (+2.18%)
Close on Nov 17, 2026Market cap $13.58MP/E –Yield –
Passage BIO operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Passage BIO's operating income for the twelve months ending Jun 30, 2026 was -$39.02M. For fiscal 2025 it was -$49.30M. The highest annual figure on record is -$37.19M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.30M | – |
| FY2024 | Dec 31, 2024 | -$70.40M | – |
| FY2023 | Dec 31, 2023 | -$108.39M | – |
| FY2022 | Dec 31, 2022 | -$138.39M | – |
| FY2021 | Dec 31, 2021 | -$185.73M | – |
| FY2020 | Dec 31, 2020 | -$112.90M | – |
| FY2019 | Dec 31, 2019 | -$37.19M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.85M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.66M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.27M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.45M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.24M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$39.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$42.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.16M | – |
| Q3 FY2021 | Sep 30, 2021 | -$47.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$38.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$39.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.59M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.77M | – |
See a number that looks wrong?